All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Kura Oncology, Roche and Syndax and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
ASAP: Conditioning vs induction + allo-HSCT in R/R AML
The AML Hub is pleased to present a visual abstract summarizing key results from the non-inferiority phase III ASAP trial comparing sequential conditioning prior to allogeneic hematopoietic stem cell transplantation (allo-HSCT) versus salvage chemotherapy followed by allo-HSCT in patients with poor response to first induction or relapsed/refractory acute myeloid leukemia.
The findings from the ASAP trial were recently presented by Schetelig1 at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition. The findings suggest that watchful waiting along with sequential conditioning prior to allo-HSCT may improve outcomes in patients with relapsed/refractory acute myeloid leukemia and with a readily available stem cell donor.
Schetelig J. In patients with relapsed/refractory AML sequential conditioning and immediate allogeneic stem cell transplantation (allo-HCT) results in similar overall and leukemia-free survival compared to intensive remission induction chemotherapy followed by allo-HCT: Results from the randomized phase III ASAP trial. Plenary scientific session #4. 64th American Society of Hematology Annual Meeting and Exposition; Dec 11, 2022; New Orleans, US.
Your opinion matters
11 votes - 19 days left ...
Newsletter
Subscribe to get the best content related to AML delivered to your inbox